<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MEPHENTERMINE SULFATE</span><br/>(me-fen'ter-meen)<br/><span class="topboxtradename">Wyamine<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">beta-adrenergic agonist (sympathomimetic)</span><br/><b>Prototype: </b>Isoproterenol<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>15 mg/mL 30 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic sympathomimetic with alpha- and predominant beta-adrenergic activity. Acts by releasing norepinephrine from tissue
         storage sites. Produces a positive inotropic action and increases cardiac output. Elevation of BP results primarily from increased
         cardiac output, and to a lesser extent from increased peripheral vasoconstriction. Antiarrhythmic action results from decrease
         in AV conduction time, atrial refractory period, and conduction time in ventricular muscle.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Heart rate may be reflectively slowed; BP elevated. Antiarrhythmic.</p>
<h1><a name="uses">Uses</a></h1>
<p>Mainly as pressor agent in treatment of hypotension secondary to ganglionic blockade or spinal anesthesia. Also has been used
         as an emergency measure in therapy of shock secondary to hemorrhage until whole blood replacement is available; as adjunct
         in treatment of cardiogenic shock, and to abolish certain cardiac arrhythmias.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Shock secondary to hemorrhage (except in emergency). Safety during pregnancy (category D) or lactation is not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Arteriosclerosis; cardiovascular disease; hypovolemia; hypertension; hyperthyroidism; patients with known hypersensitivities;
         chronically ill patients.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypotension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/IV</span> 1080 mg<br/><span class="rdage">Child:</span> <span class="rdroute">IM/IV</span> 0.4 mg/kg<br/><br/><span class="indicationtitle">Hypotensive Emergency</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 2060 mg as an IV infusion (1.2 mg/mL in D5W)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> May give undiluted.  <span class="methodtype">IV Infusion:</span> Further dilute by adding 600 mg to 50 mL of D5W.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give at a rate of 30 mg/min.  <span class="methodtype">IV Infusion:</span> Give at a rate of 15 mg/min (rate is usually prescribed by physician).  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Epinephrine,</b>
<b>hydralazine.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F) in tightly closed, light-resistant containers unless otherwise
            directed by manufacturer.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Euphoria, anorexia, weeping, nervousness, anxiety, tremor, seizures, incoherence, drowsiness. <span class="typehead">CV:</span> Tachycardia. With large doses: cardiac arrhythmias, marked elevation of BP. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Mephentermine may be ineffective in patients receiving <b>reserpine,</b>
<b>guanethidine,</b>
<span class="classification">phenothiazines</span>; <span class="classification">mao inhibitors</span>, <span class="classification">sympathomimetic amines</span>, <b>furazolidone,</b>
<b>isoniazid</b> may potentiate pressor response; <b>methyldopa,</b>
<span class="classification">tricyclic antidepressants</span> may potentiate or inhibit pressor response; <b>cyclopropane,</b>
<b>halothane</b> may cause serious arrhythmia; may increase risk of <b>digoxin</b>-induced arrhythmias. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 515 min IM; immediate IV. <span class="typehead">Duration:</span> 14 h IM; 1530 min IV. <span class="typehead">Metabolism:</span> Rapidly metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Observe and monitor BP, HR, ECG, and CVP carefully.</li>
<li>IV administration: Check BP and pulse q2min until stabilized at prescribed level, then q5min during therapy. Continue monitoring
            vital signs for at least 4560 min and longer if indicated after therapy.
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>